MANCO Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003651
MANCO AT A GLANCE
An EU-funded research project
MANCO – Monoclonal Antibodies against COVID-19 – is an EU research project
funded under the Horizon 2020 programme.
The MANCO project is coordinated by the Erasmus Medical Centre (EMC) based in The Netherlands.
The project has started on 1st March 2020 and will last about 3 years.
Project Identity Card
MANCO:
Monoclonal Antibodies against
COVID-19
Grant Agreement N° 101003651
1st March 2020 – 31st May 2023
Project dates
1st March 2020
–
31st May 2023
Coordination
Erasmus Medical
Center (EMC),
Netherlands
Consortium
8 partners from
4 Countries :
Netherlands,
Germany,
Spain & France
Funded under
Horizon 2020
EU Contribution:
3M€
The MANCO consortium at a glance
MANCO is a collaborative research project bringing together a complementary and highly experienced group of 8 partners from 4 European countries (The Netherlands, Germany,
Spain and France) that will achieve the critical mass required to deliver the ambitious objectives of this research programme.
Erasmus Medical Centre
University of Veterinary Medicine Foundation Hannover
Consejo Superior de Investigaciones Cientificas
International Alliance for Biological Standardization for Europe 
THE OVERALL CONCEPT OF THIS
COLLABORATIVE RESEARCH PROJECT
Overall, The MANCO project aims at contributing to the rapid international response against COVID-19, through preclinical and clinical evaluation of monoclonal antibodies against this coronavirus.
More specifically, MANCO will advance one lead (prophylactic and/ or therapeutic) monoclonal antibody to reach preclinical package completion, by leveraging clinical expertise, infrastructure and relevant network.
MANCO Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003651
